Cetuximab or Bevacizumab With First-Line Chemotherapy in Advanced KRAS Wild-Type Colorectal Cancer No Difference, but Not the Same

In the United States in 2017, there are projected to be 135  430 individuals newly diagnosed with colorectal cancer and 50 260 deaths from the disease with 18% to 22% having distant metastatic diseases at the time of diagnosis. Over the past decade or more, significant effort has been devoted to optimize first-line treatment for advanced and metastatic c olorectal cancer. It has been established that overall survival is similar if patients are initially treated with FOLFOX (the combination of fluororuacil with leucovorin and oxaliplatin) or FOLFIRI (the combination of fluororuacil with leucovorin and irinotecan). Several large phase 3 studies have i nvestigated the addition of targeted therapy against vascular endothelial growth factor (VEGF) (with bevacizumab) and epidermal growth fac...

from ! Medicine by Alexandros G. Sfakianakis via alwin on Inoreader http://ift.tt/2rRAQFW
via IFTTT